NCT00885495已完成1 期
The Effects of Darunavir Plus Ritonavir on the Pharmacokinetics and Pharmacodynamics of Rosuvastatin
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 17
- 试验地点
- 1
- 主要终点
- AUC of Rosuvastatin
研究概览
简要总结
This is a phase I, open-label, controlled drug interaction study to determine the effects of darunavir plus ritonavir on the pharmacokinetics of the hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, rosuvastatin, in HIV-1-seronegative subjects.
详细描述
Twelve HIV-negative healthy volunteers will be randomized to one of two groups. Group 1 would receive rosuvastatin 10mg daily (Treatment A) in interval 1 for 7 days, followed by a washout period of at least 7 days. In interval 2, darunavir/ritonavir 600/100mg bid (Treatment B) would be administered for 7 days, followed by another 7 day washout period. Lastly, in interval 3 subjects will administer darunavir/ritonavir and rosuvastatin (Treatment C) for total of 7 days. Group 2 will administer Treatment B in interval 1 for 7 days, followed by a washout period of 7 days, then treatment A in interval 2 for 7 days followed by another 7 day washout period. Group 2 would then co-administer rosuvastatin and darunavir/ritonavir for the last 7 days. Intensive PK sampling will be performed on day 7, 21 and 35 following a meal.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Absence of HIV-1/HIV-2 infection as documented by a licensed ELISA test kit within 21 days prior to study entry.
- •Male or female subjects, aged ≥ 18 and ≤ 60 years
- •Weight ≥50 kg and a Body Mass Index ([BMI], weight in kg divided by the square of height in meters) ≥18.0 and ≤ 35.0 kg/m
- •Refer to Appendix I.
- •Informed Consent Form (ICF) signed voluntarily before the first trial-related activity.
- •Able to comply with protocol requirements.
- •Healthy on the basis of a medical evaluation that reveals the absence of any clinically relevant abnormality and includes a physical examination, medical history, vital signs, and the results of blood tests and a urinalysis carried out at screening.
排除标准
- •History or evidence of current use of alcohol, barbiturate, amphetamine, recreational or narcotic drug use, which in the investigator's opinion would compromise subject's safety and/or compliance with the trial procedures.
- •Currently active significant gastrointestinal, cardiovascular, neurologic, psychiatric, metabolic, renal, hepatic, respiratory, inflammatory, or infectious disease, that in the opinion of the investigator would represent a contraindication to study enrollment.
- •Creatinine clearance of ≤ 60mL/min.
- •Currently significant diarrhea, gastric stasis, or constipation that in the investigator's opinion could influence drug absorption or bioavailability.
- •eruptions, drug allergies, food allergy, dermatitis, eczema, psoriasis, or urticaria, that in the opinion of the investigator would represent a contraindication to study enrollment.
- •Previously demonstrated clinically significant allergy or hypersensitivity to any of the excipients of the medications administered in the trial.
- •History of significant drug allergy such as, but not limited to, sulphonamides and penicillins. Prezista is a sulphonamide. The potential for cross-sensitivity between drugs in the sulphonamide class and Prezista in HIV-negative subjects is unknown.
- •Use of concomitant medication, including investigational, prescription, and over-the-counter products and dietary supplements with the following exceptions: aspirin, acetaminophen, anti-histamines such as diphenhydramine, inhalers for asthma, daily multivitamins, mineral supplements and hormonal oral contraceptives. Concomitant medication other than those listed above must have been discontinued at least 7 days before study entry.
- •Female subjects of childbearing potential without use of effective nonhormonal birth control methods, or not willing to continue practicing these birth control methods for at least 30 days after the end of the treatment period; Note: Estrogen-based hormonal contraception may not be reliable when taking Prezista, therefore to be eligible for this trial, women of childbearing potential should either:
- •use a double barrier method to prevent pregnancy (i.e., using a condom with either diaphragm or cervical cap);
- •use non-estrogen hormonal based contraceptives in combination with a barrier contraceptive (i.e., male condom, diaphragm or cervical cap, or female condom);
- •use a intrauterine device in combination with a barrier contraceptive (i.e., male condom, diaphragm or cervical cap, or female condom);
- •be not sexually active, or have a vasectomized partner (confirmed sterile).
- •Women with tubal ligation are required to use one non-hormonal contraceptive method.
- •Women who are postmenopausal for at least 2 years, and women with total hysterectomy are considered of non-childbearing potential.
- •A positive pregnancy test or breast feeding at screening.
- •Participation in an investigational drug trial within 90 days prior to the first intake of trial medication.
- •Donation of blood or plasma within 60 days preceding the first trial-related blood drawing.
- •Subjects with the following laboratory abnormalities at screening as defined by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events ("DAIDS grading table") and in accordance with the normal ranges of the trial clinical laboratory:
- •serum creatinine grade 1 or greater (≥ 1.1 x upper limit of laboratory normal range [ULN]);
- •lipase or pancreatic amylase grade 1 or greater (≥ 1.1 x ULN);
- •hemoglobin grade 1 or greater (≤ 10.9 g/dL)
- •platelet count grade 1 or greater (≤ 124.999 x 109/L);
- •absolute neutrophil count grade 1 or greater (≤ 1.3 x 109/L);
- •aspartate aminotransferase (AST) or alanine aminotransferase (ALT) grade 1 or greater (≥ 1.25 x ULN);
- •total bilirubin grade 1 or greater (≥ 1.1 x ULN),
- •any other laboratory abnormality of grade 2 or above
研究组 & 干预措施
B
Active Comparator
Darunavir+ritonavir x 7 days; Rosuvastatin x 7 days; Combination x 7 days
干预措施: darunavir, ritonavir, rosuvastatin (Drug)
A
Active Comparator
Rosuvastatin x 7 days; darunavir+ritonavir x 7 days; Combination x 7 days
干预措施: rosuvastatin, darunavir, ritonavir (Drug)
结局指标
主要结局
AUC of Rosuvastatin
时间窗: 7 days
Cmax of Rosuvastatin
时间窗: 7 days
次要结局
- To Investigate the Effect of Rosuvastatin on the Steady State Pharmacokinetics of Darunavir/Ritonavir.(45 days)
- To Compare the Change in Low-density Lipoprotein (LDL) Cholesterol With Rosuvastatin Therapy Alone, Darunavir/Ritonavir Therapy Alone and With the Co-administration of Rosuvastatin and Darunavir/Ritonavir.(45 days)
研究者
Carl J. Fichtenbaum
Professor
University of Cincinnati
研究点 (1)
Loading locations...
相似试验
已完成
1 期
PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy ParticipantsHealthy ParticipantsNCT05064800Pfizer24
已完成
1 期
TMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the 400 mg Commercial Tablet Formulation in the Presence of Low Dose Ritonavir, Under Fasted and Fed ConditionsHIV InfectionsNCT01052883Tibotec Pharmaceuticals, Ireland32
已完成
3 期
Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection.HIV-1 InfectionHIV InfectionsNCT00849160Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida100
已完成
1 期
Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy ParticipantsHepatitis CNCT02159352Bristol-Myers Squibb49
已完成
3 期
Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/RitonavirAIDS VirusHuman Immunodeficiency VirusAcquired Immunodeficiency Syndrome VirusHIV InfectionsNCT00458302Janssen-Cilag International NV256